AirSculpt Technologies sees FY25 revenue $160M-$170M, consensus $164.05M

Sees FY25 adjusted EBITDA $16M-$18MYogi Jashnani, CEO, said, “As we begin the Q2, we acknowledge we are operating in an uncertain environment, yet expect the disciplined execution of our business imperatives to help drive sequential improvement in revenue as we move through the year. We continue to focus on increasing lead generation, consultations and case conversion with our enhanced marketing and sales generation efforts, and expect the introduction of an expanded range of financing options to further assist us to achieve this goal. In addition, we have also begun to pilot skin tightening as a standalone offering, which has seen increasing interest, and believe we are uniquely positioned to capitalize on this opportunity given the effectiveness of this service as part of our body contouring procedure.” “Overall, I continue to believe that AirSculpt is an attractive business with a competitive moat that is ripe for disruption and that the best years lie ahead for AirSculpt and its shareholders. We are intently focused on executing our business imperatives, helping position us to deliver sustained long-term growth in revenue and profitability, generate free cash flow, and to increase value for our shareholders,” concluded Jashnani.